COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer

Authors: Herbst, Roy S., Majem, Margarita, Barlesi, Fabrice, Carcereny, Enric, Chu, Quincy, Monnet, Isabelle, Sanchez-Hernandez, Alfredo, Dakhil, Shaker, Camidge, D. Ross, Winzer, Leanne, Soo-Hoo, Yee, Cooper, Zachary A., Kumar, Rakesh, Bothos, John, Aggarwal, Charu, Martinez-Marti, Alex

Source: Journal of clinical oncology. 40(29):3383-3393

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100172813254.0x000001&indx=1&recIds=ETOCvdc_100172813254.0x000001